Business Wire

Sinovac Amends Shareholder Rights Plan

Share

Sinovac Biotech Ltd. (“Sinovac” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that its board of directors has amended its shareholder rights plan. The amendment extends the expiration date of the plan from February 22, 2024 to February 22, 2025.

About SINOVAC

Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of biomedical products that protect against human infectious diseases.

SINOVAC’s product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected hand-foot-mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, mumps, etc.

The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under "Category 1 Preventative Biological Products" and commercialized in China in 2016. In 2022, SINOVAC’s Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO.

SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program.

SINOVAC continually dedicates itself to pipeline development including but not limited to new technology, new vaccines as well as other biomedical products. We will constantly explore global opportunities of strategic expansion.

For more information, please visit the Company’s website at www.sinovac.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Sinovac Biotech Ltd.
Helen Yang
Tel: +86-10-8279 9720
Email: ir@sinovac.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

World Famous Soccer Star Neymar Junior Joins Forces With Fun Brands and Enters the Cocktails and Mocktails Business With His Own Brand15.4.2024 18:00:00 CEST | Press release

Neymar da Silva Santos Júnior, known as one of the best soccer players in the world, joins forces with Fun Brands, a Miami, Florida-based beverage company, to announce a new collaborative venture of innovative, all-natural spirit- and wine-based cocktails and zero alcohol mocktails launching in Brazil later this year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240415201897/en/ World Famous Soccer Star Neymar Junior Announces Collaborative Venture With Fun Brands to Enter Cocktail and Mocktail Business With Own Brand (Photo: Business Wire) “This is a great opportunity for me to celebrate in a new way with my fans worldwide, creating possibilities for connection beyond soccer, which is my life,” highlighted the All-star. “I want to share the flavors of Brazil that I love the most with my soccer fans at home and around the world in a different and irreverent way. The idea of also offering non-alcoholic beverages greatly att

First Interim Analysis of PROSPER Study Details Patient-Reported Symptom Burden of Mycosis Fungoides and Sézary Syndrome15.4.2024 15:15:00 CEST | Press release

On Friday, 12th April, 2024, Professor Julia Scarisbrick of University of Birmingham presented interim findings from the Kyowa Kirin, Inc. (Kyowa Kirin, TSA: 4151)-sponsored study, “Real-World Observational Study of Mogamulizumab in Adult Patients with Mycosis Fungoides and Sézary Syndrome (PROSPER)”, a prospective observational study evaluating the real-world impact of mogamulizumab on disease symptoms and health-related quality of life (HRQoL) in patients with these subtypes of cutaneous T-cell lymphoma (CTCL). CTCL is a rare form of non-Hodgkin lymphoma that most prominently affects the skin, presenting as patches, plaques, tumours, or reddening of the entire skin, and may be associated with severe itching. In a proportion of cases, the disease may spread to the lymph nodes, blood, and/or other organs. In the current interim analysis, symptom scores (mean) were reported for 20 adult patients with relapsed or refractory disease (8 MF; 12 SS) over their first 16 weeks of mogamulizumab

Brightcove Introduces Smart TV SDKs for Roku, Samsung, and LG Devices, Empowering Media Companies to Reach New Audiences15.4.2024 15:00:00 CEST | Press release

Brightcove (NASDAQ: BCOV), the world’s most trusted streaming technology company, today announced the launch of its new player platforms for Roku, Samsung and LG Smart TVs. The launch of the new Software Development Kits (SDKs) has unlocked advanced features within Brightcove’s industry-leading player framework, including content protection, monetization, and analytics reporting capabilities. Designed to reduce the cost and speed of high-quality app development, media companies can more effectively target the Smart TV platforms fueling media growth while delivering a consistent, engaging premium viewer experience. “Brightcove is committed to helping media companies deliver engaging and world-class reliable streaming experiences while reducing the costs traditionally associated with launching and running an OTT service," said Scott Levine, Chief Product Officer at Brightcove. “Our comprehensive platform enables media companies to benefit from out-of-the-box functionality and deliver pre

SLB Awarded Three Completion Contracts for Petrobras’ Buzios Field15.4.2024 15:00:00 CEST | Press release

SLB (NYSE: SLB) has been awarded three contracts by Petrobras (NYSE: PBR) for completion hardware and services for up to 35 subsea wells in the development of Petrobras’ offshore Buzios Wave II oilfield. The scope of the contract includes SLB’s full bore electric interval control valves and electric subsurface safety valves. The award is a catalyst toward full production system electrification for Petrobras, improving production availability via more reliable completions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240412438623/en/ Much of the technology to be deployed in Buzios and available for other operators of Brazilian pre-salt fields was developed at SLB’s Taubaté Engineering Center in Brazil for Brazilian pre-salt, in collaboration with CENPES, the Petrobras research center, and TotalEnergies. (Photo: Business Wire) By converting to electric completions, Petrobras will gain the ability to reliably control a more s

Boomi Discovery Report Reveals More Than Half of Enterprises Invest in GenAI for Integration and Automation15.4.2024 15:00:00 CEST | Press release

Boomi™, the intelligent integration and automation leader, today announced findings from its Boomi Discovery Report, commissioned by 451 Research.1 The report, based on perspectives from 650 business and IT leaders across a broad range of industries, outlines how enterprises are using Generative AI (GenAI) to integrate systems and automate processes, and how this has helped their business operations as a result. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240415795607/en/ Boomi Discovery Report Reveals More Than Half of Enterprises Invest in GenAI for Integration and Automation (Graphic: Business Wire) Every business is grappling with growing digital fragmentation – from application sprawl and disconnect between departments, to rising costs and skills shortages. GenAI delivers the promise of more efficient and cost-effective operations and improved customer and employee experiences, but only for businesses that embrace it

HiddenA line styled icon from Orion Icon Library.Eye